Vasomotor Symptoms of Menopause Pipeline Analysis | Insights into the Latest FDA and EMA Approvals, Clinical Trials, Emerging Therapies | Astellas (fezolinetant), Acer Therapeutics (pharmacokinetics)

Vasomotor Symptoms of Menopause Pipeline Analysis | Insights into the Latest FDA and EMA Approvals, Clinical Trials, Emerging Therapies | Astellas (fezolinetant), Acer Therapeutics (pharmacokinetics)
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 9+ key pharma and biotech companies are working on 9+ pipeline drugs in the Vasomotor Symptoms of Menopause therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Vasomotor Symptoms of Menopause Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Vasomotor Symptoms of Menopause Market. 

The Vasomotor Symptoms of Menopause Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Vasomotor Symptoms of Menopause Pipeline Analysis

Vasomotor Symptoms of Menopause Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about emerging therapies for the treatment of Vasomotor Symptoms of Menopause and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vasomotor Symptoms of Menopause Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Vasomotor Symptoms of Menopause market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

DelveInsight’s Report covers around 9+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Latest Clinical and Commercial Developments in the Vasomotor Symptoms of Menopause Therapeutics Market

On September 29, 2022, Astellas Pharma Inc. (TSE: 4503) announced that the European Medicines Agency (EMA) had accepted for regulatory review the company’s marketing authorization application (MAA) for fezolinetant, an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

On March 30, 2022, Acer Therapeutics Inc. (Nasdaq: ACER) announced the enrollment of the first patient in its Phase 2a trial, evaluating the efficacy, safety, and pharmacokinetics (PK) of ACER-801 (osanetant) at different doses, compared to placebo, for the treatment of moderate to severe Vasomotor Symptoms (VMS) associated with menopause.

Learn How the Ongoing Clinical & Commercial Activities will Affect the Vasomotor Symptoms of Menopause Therapeutic Segment:

Vasomotor Symptoms of Menopause Therapeutics Landscape

Hormone therapy, antidepressant drugs, and lifestyle modification are ways to manage Vasomotor Symptoms of Menopause. As per DelveInsight, there are approx. 9+ key companies which are developing new therapies for Vasomotor Symptoms of Menopause. Currently, Mithra Pharmaceuticals has its Vasomotor Symptoms of Menopause drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Vasomotor Symptoms of Menopause Therapeutics Market include:

• Mithra Pharmaceuticals

• Acer Therapeutics

• QUE Oncology

• Bayer

• Endoceutics

• Astellas Pharma

• Mitsubishi Tanabe Pharma

• MenoGenix

And many others

Vasomotor Symptoms of Menopause Drugs Covered in the report include:

• Donesta: Mithra Pharmaceuticals

• Q-122: QUE Oncology

And many others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Vasomotor Symptoms of Menopause Current Treatment Patterns

4. Vasomotor Symptoms of Menopause – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Vasomotor Symptoms of Menopause Late Stage Products (Phase-III)

7. Vasomotor Symptoms of Menopause Mid-Stage Products (Phase-II)

8. Vasomotor Symptoms of Menopause Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Vasomotor Symptoms of Menopause Discontinued Products

13. Vasomotor Symptoms of Menopause Product Profiles

14. Key Companies in the Vasomotor Symptoms of Menopause Market

15. Key Products in the Vasomotor Symptoms of Menopause Therapeutics Segment

16. Dormant and Discontinued Products

17. Vasomotor Symptoms of Menopause Unmet Needs

18. Vasomotor Symptoms of Menopause Future Perspectives

19. Vasomotor Symptoms of Menopause Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Listeriosis Market

“Listeriosis Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Listeriosis Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States